Abstract

Herein, a novel linear DNA nanostructure (LDN)-based delivery system was designed and prepared to efficiently co-deliver both epirubicin (Epi), as a chemotherapy drug, and antimiR-10b, as a therapeutic oligonucleotide, into breast cancer cells (MCF-7 and 4T1 cells). Firstly, the LDN, comprised of AS1411 aptamer (targeting agent), FOXM1 Apt (therapeutic aptamer), and complementary strand (linker), was prepared to carry both Epi and antimiR-10b. This targeted system is highly stable in serum and easy to be constructed. The Epi-loaded LDN structure showed a remarkable internalization for target cells (MCF-7 and 4T1 cells, nucleolin positive) in comparison with CHO cells (nucleolin negative, non-target). Furthermore, based on the MTT assay, the Epi-loaded LDN significantly decreased the cell viability of MCF-7 and 4T1 cells, while the non-targeted cells indicated less cytotoxicity for this structure, showing the targeting ability of Epi-loaded LDN. Moreover, the ability of tumor growth inhibition of the Epi-loaded LDN structure was significantly much more than free Epi and LDN in tumor-bearing mice, suggesting the significance of combination therapy for tumor treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.